LCLei Chen

Lei Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lei Chen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Fuqiang Wen

    Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China

    2 shared publications
  • Tao Wang

    Division of Internal Medicine, West China Hospital of Sichuan University, Chengdu 610041, China

    2 shared publications
  • Bei-Bei Sun

    Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China

    1 shared publication
  • Chun Wan

    Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China

    1 shared publication
  • Dai-Shun Liu

    Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China

    1 shared publication
  • Dan Xu

    Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China

    1 shared publication

Latest Publications

  • Open Access

    Can cholesterol be used to distinguish pleural exudates from transudates? evidence from a bivariate meta-analysis

    by Yongchun Shen, Hong Zhu, Chun Wan, Lei Chen, Tao Wang, Ting Yang, Fuqiang Wen

    Many studies have investigated whether pleural cholesterol levels can aid in diagnosis of pleural exudates, and the results have varied considerably. To gain a more reliable answer to this question, we meta-analyzed the literature on using pleural cholesterol or the ratio of cholesterol in pleural fluid to cholesterol in serum (P/S cholesterol ratio) as diagnostic tests to help identify pleural exudates.


  • Open Access

    The -173 G/C Polymorphism of the MIF Gene and Inflammatory Bowel Disease Risk: A Meta-Analysis

    by Yongchun Shen, Shujin Guo, Ting Yang, Liuqun Jia, Lei Chen, Jing An, Tao Wang, Fuqiang Wen

    The -173 G/C polymorphism in the macrophage migration inhibitory factor (MIF) gene has been implicated in susceptibility to inflammatory bowel disease (IBD), but the results are inconclusive. The present meta-analysis aimed to investigate the overall association between the -173 G/C polymorphism and IBD risk. We searched in Pubmed, and Embase for studies evaluating the association between the -173G/C gene polymorphism and IBD risk. Data were extracted and statistical analysis was performed using Revman 5.1 and STATA 12.0 software. A total of seven publications involving 4729 subjects (2282 IBD cases and 2447 controls) were included in this meta-analysis. Combined analysis revealed a clear association between this polymorphism and IBD susceptibility (OR = 1.48, 95% CI: 1.10–2.00, p = 0.009 for CC vs. CG + GG). Subgroup analysis by ethnicity showed that the IBD risk associated with the -173G/C gene polymorphism was significantly elevated among Asians (OR = 1.79, 95% CI: 1.08–2.96, p = 0.02), but not among Caucasians. Subgroup analysis by disease suggested that the -173G/C gene polymorphism is a risk factor for ulcerative colitis (OR = 1.62, 95% CI: 1.10–2.37, p = 0.01), but that it was not associated with Crohn’s disease. This meta-analysis suggests that the -173 G/C polymorphism in the macrophage MIF gene contributes to IBD susceptibility, specifically in Asian populations. Further studies are needed to validate these findings.


  • Open Access

    Blockade of advanced glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats

    by Lei Chen, Tao Wang, Xun Wang, Bei-Bei Sun, Ji-Qiong Li, Dai-Shun Liu, Shang-Fu Zhang, Lin Liu, Dan Xu, Ya-Juan Chen, et al.

    Advanced glycation end products (AGEs) have been proposed to be involved in pulmonary fibrosis, but its role in this process has not been fully understood. To investigate the role of AGE formation in pulmonary fibrosis, we used a bleomycin (BLM)-stimulated rat model treated with aminoguanidine (AG), a crosslink inhibitor of AGE formation.